Free Trial

Tiziana Life Sciences (TLSA) Competitors

Tiziana Life Sciences logo
$1.51 +0.02 (+1.34%)
Closing price 04:00 PM Eastern
Extended Trading
$1.52 +0.01 (+0.99%)
As of 05:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TLSA vs. TRVI, ANAB, IMTX, DAWN, MRVI, AUTL, STOK, URGN, PHAT, and RLAY

Should you be buying Tiziana Life Sciences stock or one of its competitors? The main competitors of Tiziana Life Sciences include Trevi Therapeutics (TRVI), AnaptysBio (ANAB), Immatics (IMTX), Day One Biopharmaceuticals (DAWN), Maravai LifeSciences (MRVI), Autolus Therapeutics (AUTL), Stoke Therapeutics (STOK), Urogen Pharma (URGN), Phathom Pharmaceuticals (PHAT), and Relay Therapeutics (RLAY). These companies are all part of the "pharmaceutical products" industry.

Tiziana Life Sciences vs. Its Competitors

Tiziana Life Sciences (NASDAQ:TLSA) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Tiziana Life Sciences has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.

In the previous week, Trevi Therapeutics had 7 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 8 mentions for Trevi Therapeutics and 1 mentions for Tiziana Life Sciences. Trevi Therapeutics' average media sentiment score of 0.55 beat Tiziana Life Sciences' score of 0.00 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tiziana Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Trevi Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

95.8% of Trevi Therapeutics shares are held by institutional investors. 39.8% of Tiziana Life Sciences shares are held by insiders. Comparatively, 18.3% of Trevi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Tiziana Life Sciences' return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tiziana Life SciencesN/A N/A N/A
Trevi Therapeutics N/A -58.41%-52.52%

Trevi Therapeutics has a consensus price target of $20.88, suggesting a potential upside of 238.33%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Trevi Therapeutics is more favorable than Tiziana Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tiziana Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Trevi Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
3 Strong Buy rating(s)
3.30

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life SciencesN/AN/A-$11.86MN/AN/A
Trevi TherapeuticsN/AN/A-$47.91M-$0.45-13.71

Summary

Trevi Therapeutics beats Tiziana Life Sciences on 8 of the 12 factors compared between the two stocks.

Get Tiziana Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TLSA vs. The Competition

MetricTiziana Life SciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$174.10M$2.90B$5.51B$8.96B
Dividend YieldN/A2.44%5.25%4.02%
P/E RatioN/A21.0128.0520.15
Price / SalesN/A294.68438.14127.85
Price / CashN/A41.8337.0657.97
Price / Book37.757.868.125.62
Net Income-$11.86M-$54.95M$3.16B$248.50M
7 Day Performance-3.82%6.24%4.40%5.54%
1 Month Performance6.34%5.70%4.09%7.52%
1 Year Performance86.19%8.08%34.53%22.06%

Tiziana Life Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TLSA
Tiziana Life Sciences
0.8158 of 5 stars
$1.51
+1.3%
N/A+81.6%$174.10MN/A0.008News Coverage
Positive News
TRVI
Trevi Therapeutics
3.2488 of 5 stars
$5.95
flat
$20.88
+250.8%
+115.4%$697.89MN/A-13.2220
ANAB
AnaptysBio
2.287 of 5 stars
$23.45
-1.3%
$42.38
+80.7%
-4.8%$697.79M$91.28M-4.84100
IMTX
Immatics
3.1571 of 5 stars
$5.53
-3.2%
$14.67
+165.2%
-52.6%$694.05M$168.65M-32.53260
DAWN
Day One Biopharmaceuticals
1.7048 of 5 stars
$6.63
-2.5%
$30.57
+361.1%
-55.3%$689.27M$131.16M-9.3460
MRVI
Maravai LifeSciences
3.6942 of 5 stars
$2.60
-2.6%
$6.64
+155.3%
-62.4%$679.94M$259.18M-2.28610News Coverage
AUTL
Autolus Therapeutics
2.1435 of 5 stars
$2.26
-4.6%
$9.32
+312.4%
-36.7%$630.76M$10.12M-2.57330
STOK
Stoke Therapeutics
3.8846 of 5 stars
$11.69
+1.8%
$23.20
+98.5%
-7.2%$626.77M$36.56M14.80100
URGN
Urogen Pharma
4.5377 of 5 stars
$13.49
-0.7%
$32.86
+143.6%
-14.8%$626.14M$90.40M-4.24200Analyst Forecast
Gap Up
PHAT
Phathom Pharmaceuticals
3.3195 of 5 stars
$8.66
-2.9%
$17.50
+102.1%
-13.5%$622.74M$55.25M-1.65110
RLAY
Relay Therapeutics
2.5453 of 5 stars
$3.55
-2.2%
$17.67
+397.7%
-44.6%$622.34M$10.01M-1.59330

Related Companies and Tools


This page (NASDAQ:TLSA) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners